Targeting FAK in anticancer combination therapies.
Targeting FAK in anticancer combination therapies.
复制标题
DOI:
10.1038/s41568-021-00340-6
复制
发表时间:
2021-05
期刊:
影响因子:
--
通讯作者:
Frame MC
中科院分区:
文献类型:
--
作者:
Dawson JC;Serrels A;Stupack DG;Schlaepfer DD;Frame MC
Focal adhesion kinase (FAK) is both a non-receptor tyrosine kinase and an adaptor protein that primarily regulates adhesion signalling and cell migration, but FAK can also promote cell survival in response to stress. FAK impacts on a diverse range of cancer cell functions mediated by both its kinase and scaffolding functions. It is commonly overexpressed in cancer and has been considered a high value druggable target for therapy, with multiple FAK kinase inhibitors currently in development. Substantial evidence has emerged implying that it is as clinical combination strategies that FAK targeting will be most effective, so as to reverse failure of chemotherapies or targeted therapies and enhance efficacy of immune-based treatments of solid tumours. Here we discuss the recent pre-clinical evidence that implicates FAK in anti-cancer therapeutic resistance, leading to the view that FAK kinase inhibitors will have their greatest utility as combination therapies in stratified contexts.
登录
查看更多内容
DOI:
10.4049/jimmunol.1301587
发表时间:
2013-12-15
期刊:
Journal of immunology (Baltimore, Md. : 1950)
影响因子:
--
作者:
Chapman NM;Connolly SF;Reinl EL;Houtman JC
通讯作者:
Houtman JC
影响因子:
7.7
作者:
Canel, Marta;Taggart, David;Serrels, Alan
通讯作者:
Serrels, Alan
影响因子:
16
作者:
Courtney AH;Amacher JF;Kadlecek TA;Mollenauer MN;Au-Yeung BB;Kuriyan J;Weiss A
通讯作者:
Weiss A
影响因子:
11.4
作者:
Acebron, Ivan;Righetto, Ricardo D.;Lietha, Daniel
通讯作者:
Lietha, Daniel
影响因子:
7.7
作者:
Diaz Osterman, Carlos J.;Ozmadenci, Duygu;Schlaepfer, David D.
通讯作者:
Schlaepfer, David D.